Dublin, April 12, 2024 (GLOBE NEWSWIRE) -- The "CDK9 inhibitor - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.
"Cyclin-Dependent Kinase 9 (CDK9) Inhibitor - Pipeline Insight, 2024" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Cyclin-Dependent Kinase 9 (CDK9) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Emerging Drugs Chapters
This segment of the Cyclin-Dependent Kinase 9 (CDK9) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Emerging Drugs
Dinaciclib: Merck & CoDinaciclib (SCH 727965) is a small molecule inhibitor of cyclin-dependent kinases. Dinaciclib demostrates potent and selective inhibition of CDK2, CDK5, CDK1, and CDK9 activity. Dinaciclib inhibits cell cycle progression and proliferation in various tumor cell lines in vitro. Dinaciclib is a product of a drug discovery collaboration between Pharmacopeia (later Ligand Pharmaceuticals) and Schering-Plough (later Merck & Co.). The drug is currently in phase 3 of clinical trials for the treatment of Chronic lymphocytic leukaemia.
KB-0742: Kronos BioKB-0742 is a selective, orally bioavailable inhibitor of CDK9, a global regulator of transcription and a critical node in the oncogenic TRN resulting from MYC overexpression. MYC is a well-known transcription factor and cancer driver that is dysregulated in a significant proportion of human cancers, often via genomic copy number gain, or amplification. The drug is currently in phase 1/2 of clinical trials for the treatment of Solid tumours.
Alvocidib: Sumitomo Dainippon Pharma OncologyAlvocidib is an investigational, intravenously administered, small molecule cyclin-dependent kinase 9 (CDK9) inhibitor.Inhibiting CDK9 is thought to downregulate the transcription of target genes, including myeloid cell leukemia 1 (MCL-1), reducing leukemic blast viability in MCL-1-dependent, hematologic malignancies. The drug is currently in phase 2 of clinical trials for the treatment of acute myeloid leukemia.
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different Cyclin-Dependent Kinase 9 (CDK9) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
Major Players working on Cyclin-Dependent Kinase 9 (CDK9) Inhibitor
There are approx. 15+ key companies which are developing the Cyclin-Dependent Kinase 9 (CDK9) Inhibitor. The companies which have their Cyclin-Dependent Kinase 9 (CDK9) Inhibitor drug candidates in the most advanced stage, i.e. phase III include, Merck & Co.
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cyclin-Dependent Kinase 9 (CDK9) Inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cyclin-Dependent Kinase 9 (CDK9) Inhibitor drugs.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Cyclin-Dependent Kinase 9 (CDK9) Inhibitor R&D. The therapies under development are focused on novel approaches for Cyclin-Dependent Kinase 9 (CDK9) Inhibitor.
Key Players
- Merck & Co
- Kronos Bio
- Sumitomo Dainippon Pharma Oncology
- AstraZeneca
- Kino Pharma
- Cyclacel Pharmaceuticals
- Bayer
- MEI Pharma
- Syros Pharmaceuticals
- BioTheryX
- Le Sun Pharmaceuticals
- NeoSome Life Sciences
- Adastra Pharmaceuticals/S*Bio
- Virostatics
- GenFleet Therapeutics
- ASINEX
Key Products
- Dinaciclib
- KB-0742
- Alvocidib
- AZD 4573
- TP 1287
- FIT 039
- BAY 1251152
- Seliciclib
- Fadraciclib
- Voruciclib
- SY 5609
- BTX A51
Research programme:
- cancer therapeutics- NEOS 518
- Zotiraciclib
Research programme:
- anticancer therapeutics
- Research programme: cyclin-dependant kinases
- GFH 009
Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical.
Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Report Insights
- Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/2tcp99
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
